^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KD6001

    i
    Other names: KD6001
    Associations

    News

    Trials
    Company:
    Shanghai Kanda Biotech
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    12ms
    KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors (clinicaltrials.gov)
    P1/2, N=85, Not yet recruiting, Shanghai Kanda Biotechnology Co., Ltd. | Initiation date: Jul 2023 --> Apr 2024 | Trial primary completion date: Dec 2024 --> Apr 2025
    Trial initiation date • Trial primary completion date • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • KD6001
    over1year
    KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors (clinicaltrials.gov)
    P1/2, N=85, Not yet recruiting, Shanghai Kanda Biotechnology Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • KD6001